There are three primary types: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma ... Overview and More Understanding Stage 3A Non-Small Cell Lung Cancer Stage 3B Non-Small Cell Lung ...

Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase III drugs for Squamous Non-Small Cell Lung ...

For information, the company have announced that the Phase III KEYLYNK-008 Trial did not meet its co-primary endpoints in demonstrating an improvement in overall survival (OS) or progression-free ...

Researchers have looked at the ratio of some types of white blood cells to predict prognosis with early stage tumors ... syndromes may help diagnose at least some early-stage lung cancer.

The results of CheckMate 77T showcase the improved event-free survival for patients with resectable non–small cell lung cancer who receive nivolumab in both the neoadjuvant and adjuvant setting ...

Demographic disparities were observed in survival trends of patients with esophageal squamous cell carcinoma, with male sex and non-Hispanic Black race associated ... researchers analyzed data from ...

The number of lung cancer diagnoses amongst people who have never smoked is increasing globally, according to the World ...

Adjuvant cemiplimab prolonged DFS compared with placebo for certain patients with cutaneous squamous cell ... patients with basal cell carcinoma or non-small cell lung cancer.

Estimated geographical and temporal distribution of lung-cancer incidence varied across the four main subtypes worldwide. Our ...

Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...